GnRH Antagonist for Advanced Prostate Cancer Treatment
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Intramuscular (depot formulation)
Route
3 recommended
Sites
Once daily
Frequency
Preparation
Abarelix vial (lyophilized powder or solution)
Bacteriostatic water or sterile sodium chloride for reconstitution
Alcohol swabs for cleaning vial tops and injection sites
Appropriately sized syringes with fine-gauge needles (27-30 gauge)
Sharps disposal container
Pro tip
Prepare all supplies on a clean surface before you begin. Having everything ready makes the process smoother and more sterile.
Mixing
Wash your hands thoroughly with soap and water. Gather all supplies on a clean, flat surface.
Remove the plastic cap from the peptide vial and wipe the rubber stopper with an alcohol swab. Let it air dry.
Draw the appropriate amount of bacteriostatic water into a sterile syringe.
Insert the needle into the vial at an angle, aiming at the inside wall of the vial. Slowly push the plunger to let the water trickle down the glass wall -- do NOT squirt directly onto the powder.
Once all water is added, gently swirl the vial in a slow circular motion. Never shake the vial, as this can damage the peptide bonds.
Continue swirling until the powder is completely dissolved and the solution is clear. If particles remain, let the vial sit for a few minutes and swirl again.
Label the vial with the date of reconstitution, the peptide name, and the concentration (e.g. 250mcg per 0.1mL).
Example calculation
Add the recommended volume of bacteriostatic water to the Abarelix vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Dose calculation
Your dose of Abarelix is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Pro tip
Always add the bacteriostatic water slowly, letting it run down the side of the vial. Never shake the vial -- swirl gently to avoid damaging the peptide.
Location
Site 01
Abdomen
Pinch the skin 2 inches from navel. Avoid the area directly around the belly button. Rotate between left and right sides.
Site 02
Outer Thigh
Middle third of the outer thigh. Keep at least 4 inches above the knee and below the hip. Alternate legs each injection.
Site 03
Upper Arm
Back or outer area of the upper arm. This site may require assistance from another person for proper technique.
Rotate between 3 sites to prevent tissue buildup and ensure consistent absorption.
Pro tip
Rotate your injection sites with each dose to prevent lipohypertrophy (buildup of fatty tissue). Keep a simple log of where you last injected.
Step by step
Wash your hands thoroughly with soap and water before handling supplies
Clean the injection site with an alcohol swab and let it air dry completely
Pinch a fold of skin at the chosen injection site
Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
Inject the medication slowly and steadily over 5-10 seconds
Release the skin fold and remove the needle, applying gentle pressure with a clean swab
Rotate injection sites to prevent tissue irritation or lipodystrophy
Dispose of the needle safely in a sharps container—never recap or reuse needles
Pro tip
This peptide uses subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training. Inject at a 45-90 degree angle into pinched skin. Aspirate before injecting to ensure you haven't hit a blood vessel.
Timing
Optimal timing
Best time
Administer Abarelix at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Abarelix injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
Stacking notes
Abarelix should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Intramuscular injection (depot formulation)—rotate sites if applicable
Maintain a consistent schedule for optimal results with Abarelix. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Dosing tiers
Dose
100 mg
Frequency
Day 1, 15, 29, then every 4 weeks
Duration
Up to 12 months (effectiveness beyond 12 months not established)
This is the FDA-approved dose for advanced prostate cancer. A 100 mg shot is given into the buttock muscle on day 1, 15, and 29, then once every 4 weeks. The drug was sold as Plenaxis. [4]
Preservation
Before mixing
Store Abarelix in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After mixing
Once reconstituted, Abarelix should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Shelf life after mixing
Use within the timeframe specified on product labeling (typically 14-28 days refrigerated)
Signs of degradation
Discard the vial immediately if you notice any of these:
Solution appears cloudy, discolored, or contains visible particles (should be clear)
Product has been exposed to temperatures outside the recommended storage range
Product has been frozen (unless specifically designed for freeze-thaw stability)
Expiration date has passed or reconstituted solution has exceeded its use-by date
Unusual odor, color change, or visible contamination
Important
When to stop
Severe or worsening side effects that don't improve with dose adjustment or supportive care
Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
Your healthcare provider recommends discontinuation based on your clinical response
Development of any new medical condition that may be contraindicated with Abarelix
Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
Abnormal lab results or clinical markers that suggest adverse effects
Abarelix should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Clean technique checklist
Wash hands thoroughly with soap and water before handling supplies
Swab vial tops and injection site with alcohol and let dry
Never touch the needle tip or allow it to contact non-sterile surfaces
Use a new syringe and needle for each injection
Dispose of used sharps in a proper sharps container
Store reconstituted peptides according to the storage instructions above
Published research
Patel S, Saxena B, Mehta P · 2024
GnRH antagonists like abarelix provide rapid testosterone suppression without the initial hormone surge seen with agonists. These peptides offer faster onset of action and lower cardiovascular risk, making them revolutionary therapy for advanced prostate cancer and other hormone-dependent diseases.
Moul JW · 2014
Degarelix, as an LHRH antagonist, achieved very rapid testosterone suppression with no testosterone surge unlike agonists. Clinical studies showed patients experienced sustained suppression below castration levels with better disease control than traditional LHRH agonists.
Van Poppel H, Klotz L · 2012
GnRH antagonists achieved faster castration, suppressed prostate-specific antigen more effectively, and avoided testosterone surge altogether. These benefits suggested antagonists could replace agonists as first-line therapy, potentially delaying the onset of castration-resistant disease.
U.S. Food and Drug Administration · 2003
Recommended dose is 100 mg administered intramuscularly to the buttock on Day 1, 15, 29 (week 4) and every 4 weeks thereafter; effectiveness beyond 12 months not established.
Head to head